Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
31.08
-1.30 (-4.01%)
May 13, 2025, 4:00 PM - Market closed
Legend Biotech Employees
Legend Biotech had 2,609 employees as of December 31, 2024. The number of employees increased by 783 or 42.88% compared to the previous year.
Employees
2,609
Change (1Y)
783
Growth (1Y)
42.88%
Revenue / Employee
$279,150
Profits / Employee
-$83,614
Market Cap
5.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,609 | 783 | 42.88% |
Dec 31, 2023 | 1,826 | 436 | 31.37% |
Dec 31, 2022 | 1,390 | 319 | 29.79% |
Dec 31, 2021 | 1,071 | 189 | 21.43% |
Dec 31, 2020 | 882 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LEGN News
- 20 hours ago - Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Legend Biotech Reports First Quarter 2025 Results and Recent Highlights - GlobeNewsWire
- 5 weeks ago - Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst - Benzinga
- 2 months ago - Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights - GlobeNewsWire
- 4 months ago - Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4) - Seeking Alpha
- 5 months ago - Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma - GlobeNewsWire